|
|
Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com |
|
AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SmallCapVoice.com, Inc. and Wuhan General Group, Inc. (OTC PINK: WUHN), please note that additional content and quotations have become available. The corrected release follows:
SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announced today that a new audio interview with the Company is now available.
The interview featuring an overview of WUHN’s current news and moves can be heard at https://www.smallcapvoice.com/tag/wuhn/.
Jeff Robinson, CEO of Wuhan, called in to SmallCapVoice.com to go over the business model and markets that his Company operates in. Wuhan is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical cannabidiol (CBD) space, as well as the promising psilocybin medical health sector.
The Company’s subsidiary MJ MedTech is a cosmetics and food for special medical purposes (FSMP) company with leading alternative plant-based cannabinoids and psilocybin medical research, formulation and delivery system divisions. Cannabinoids and mushroom-based formulations are under the Dr. AnnaRx™ and Medspresso™ brands. READ MORE |
|
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.
About Penny Stocks |
|
|
